Immtech Pharma put a hold on its Phase III clinical program for pafuramidine, a treatment for pneumocystis pneumonia (PCP) (an HIV/AIDS related illness) and African sleeping sickness. Immtech is conducting worldwide trials of pafuramidine and recently added a China arm. The drug was given Fast Track status by the SFDA earlier this year. In South African labs, observers noted that trial volunteers had abnormally high liver toxicity readings. More details...

Stock Symbol: (AMEX: IMM)